#ASCO14 - Poster: Circulating tumor cell count and lactate dehydrogenase levels are prognostic factors in patients with metastatic CRPC progressing during or following docetaxel treated in the orteronel phase 3 ELM-PC 5 trial

CHICAGO, IL USA (UroToday.com) - Presented by Howard I. Scher,1 Karim Fizazi,2 Shih Yuan Lee,3 David B. MacLean,3 Iain J. Webb,4 Niels Borgstein,3 and Robert Dreicer5 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 scher elmpc thumb

1Memorial Sloan Kettering Cancer Center, New York, NY USA
2Institut Gustave Roussy, University of Paris Sud, Villejuif, France
3Takeda Pharmaceuticals International Co., Cambridge, MA USA
4Millennium: The Takeda Oncology Company, Cambridge, MA USA
5Cleveland Clinic, Cleveland, OH USA